Lowenstein Sandler LLP | The contents of this website contain attorney advertising. | Results may vary depending on your particular facts and legal circumstances.
Access the profiles of the more than 350 Lowenstein Sandler lawyers who provide critical legal counsel to clients in virtually every sector of the global economy...
Discover the latest updates and developments about Lowenstein Sandler...
Access our insightful thought leadership, including articles, client alerts, and blog posts...
*James Assmann is currently on a secondment with Ambrx, Inc. through approximately May 31, 2024.
James Assmann’s practice focuses on capital markets and securities matters, as well as strategic life sciences transactions and general corporate matters.
His experience includes initial public offerings (IPOs), private investments in public equity (PIPEs), registered direct offerings (RDs), at the market offerings (ATMs), special purpose acquisition companies (SPACs), and securities laws and SEC compliance.
James also represents pharmaceutical, biotechnology, consumer healthcare, and medical device companies on strategic transactions and general corporate matters, including mergers and acquisitions, licensing, research, development and collaboration agreements, commercial agreements, and various corporate governance matters.
A former associate at an Am Law 50 firm, James also has over 12 years of prior experience at several global pharmaceutical corporations, including Merck, where he served in the Office of the General Counsel, and Novartis, where he worked in preclinical research and development.
Rutgers School of Law (2019, J.D.); Corporate and Business Law Certificate
The College of Saint Elizabeth (2014, M.S., Healthcare Management)
Loyola University Maryland (2008, B.B.A.); International Business Concentration
VCard
Download
Add to Folder
